Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide

John Greene1,2, Anne-Marie Baird1,3,4,5, Orla Casey1, Lauren Brady1, Gordon Blackshields1,2, Marvin Lim1,2, Odharnaith O’Brien6, Steven G. Gray3,4,7,8, Raymond McDermott2,6,9 & Stephen P. Finn1,3,4,6

Most forms of castration-resistant prostate cancer (CRPC) are dependent on the androgen receptor (AR) for survival. While, enzalutamide provides a substantial survival benefit, it is not curative and many patients develop resistance to therapy. Although not yet fully understood, resistance can develop through a number of mechanisms, such as AR copy number gain, the generation of splice variants such as AR-V7 and mutations within the ligand binding domain (LBD) of the AR. circular RNAs (circRNAs) are a novel type of non-coding RNA, which can regulate the function of miRNA, and may play a key role in the development of drug resistance. circRNAs are highly resistant to degradation, are detectable in plasma and, therefore may serve a role as clinical biomarkers. In this study, AR-V7 expression was assessed in an isogenic model of enzalutamide resistance. The model consisted of age matched control cells and two sub-line clones displaying varied resistance to enzalutamide. circRNA profiling was performed on the panel using a high throughput microarray assay. Bioinformatic analysis identified a number of differentially expressed circRNAs and predicted five miRNA binding sites for each circRNA. miRNAs were stratified based on known associations with prostate cancer, and targets were validated using qPCR. Overall, circRNAs were more often down regulated in resistant cell lines compared with control (588 vs. 278). Of particular interest was hsa_circ_0004870, which was down-regulated in enzalutamide resistant cells (p ≤ 0.05, vs. sensitive cells), decreased in cells that highly express AR (p ≤ 0.01, vs. AR negative), and decreased in malignant cells (p ≤ 0.01, vs. benign). The associated parental gene was identified as RBM39, a member of the U2AF65 family of proteins. Both genes were down-regulated in resistant cells (p < 0.05, vs. sensitive cells). This is one of the first studies to profile and demonstrate discrete circRNA expression patterns in an enzalutamide resistant cell line model of prostate cancer. Our data suggests that hsa_circ_0004870, through RBM39, may play a critical role in the development of enzalutamide resistance in CRPC.

Prostate cancer (PCa) is the second leading cause of male cancer mortality in Western Europe and the United States1. Androgen deprivation therapy (ADT) is the mainstay of treatment1, with an average initial response of approximately 18 months, however resistance to ADT inevitably develops. This leads to castration-resistant prostate cancer (CRPC), which is currently incurable2. Although resistant to ADT, CRPC continues to rely on androgens via androgen receptor (AR) signalling3.

1Department of Histopathology and Morbid Anatomy, School of Medicine, Trinity College Dublin, Dublin 8, Ireland. 2Department of Medical Oncology, Tallaght Hospital, Dublin 24, Ireland. 3Thoracic Oncology Research Group, Trinity Translational Medical Institute, St. James’s Hospital, Dublin 8, Ireland. 4Department of Clinical Medicine, Trinity College Dublin, Dublin 2, Ireland. 5Cancer and Ageing Research Program, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia. 6Department of Histopathology, St. James’s Hospital, Dublin 8, Ireland. 7Labmed Directorate, St. James’s Hospital, Dublin 8, Ireland. 8HOPE Directorate, St. James’s Hospital, Dublin 8, Ireland. 9Department of Medical Oncology, St. Vincent’s Hospital, Dublin 4, Ireland. Correspondence and requests for materials should be addressed to J.G. (email: greenejo@tcd.ie)
Enzalutamide is a targeted AR inhibitor that competitively binds to the ligand-binding domain (LBD) of the AR. It inhibits AR translocation, recruitment of AR cofactors, and AR binding to DNA. In previous phase 3 studies, enzalutamide prolonged overall and progression-free survival in patients who were chemotherapy naïve, and in those who had previously received chemotherapy. As a result, therapy with second generation anti-androgens has been recognised as a standard of care for advanced PCA. Nevertheless, approximately 20 to 40% of patients will present with intrinsic resistance to enzalutamide as determined by sustained elevated prostate-specific antigen (PSA) levels and radiological or clinical progression. Furthermore, patients who have an initial objective response will eventually develop secondary resistance. While the exact mechanisms of enzalutamide resistance are yet to be fully understood, it appears that AR gene amplification emerges during treatment with ADT and facilitates tumour growth in low androgen concentrations. Additionally, expression of the AR splice variant-7 (AR-V7), which is a truncated form of the AR lacking the ligand-binding domain, has been shown to be associated with resistance to enzalutamide. A number of mutations have also been identified in the AR in patients who are resistant to enzalutamide, such as F876L and may contribute to resistance.

With the advances in experimental technology and bioinformatics, our understanding of RNA families has improved, as well as our general understanding of the importance of RNA associated interactions and subcellular locations. One type of RNA family is non-coding RNA (ncRNA). ncRNA comprises of several different classes, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), both of which are areas of active investigation in PCA. A recently discovered novel ncRNA, called circular RNA (circRNA), may play an important role in cancer initiation, development, and progression. circRNAs are RNA molecules with covalently joined 3' and 5' ends formed by back-splice events, thus presenting as closed continuous loops, which makes them highly stable. They typically comprise of one to several coding exons of otherwise linear messenger RNAs (mRNAs) and range between a few hundreds and thousands of nucleotides in length. Their high abundance, stability and evolutionary conservation between species suggest that they may have an important biological regulatory role. circRNAs have been identified in a number of cancers including PCA, suggesting a potential role as a biomarker or therapeutic target. Although, their role in cancer has yet to be fully elucidated, recent research suggests they can bind RNA-binding proteins (RBPs), translate peptides and confer resistance to therapy. miRNAs have previously been shown to affect a wide array of biological processes and have an important role in regulating gene expression in cancer, where they act through downstream tumour-suppressive mRNAs. It has been proposed that circRNAs can act as a miRNA 'sponge' thereby modifying miRNA activity through sequestration, thus altering mRNA target gene expression. circRNAs are extremely stable and resistant to RNA degradation, and as such they have the potential to translate into clinically useful blood based 'liquid biopsies' to detect early stage disease and monitor treatment response in real time. The goal of this study was to determine if circRNAs were differentially expressed in enzalutamide resistant cells, and to examine the circRNA-mRNA network involved in the development of drug resistance.

Results and Discussion

AR-V7 is elevated in enzalutamide resistant cells. While it is known that the resistant cell lines used in this study harbour increased F876L, which is an agonist-switch mutation resulting in increased resistance to enzalutamide, there is no information on its association with AR-V7 levels. We detected AR-FL and AR-V7 expression in the cell line model using a standard curve qPCR method. While, AR-FL copy number was consistent across the panel (Fig. 1A), AR-V7 copy number varied depending on enzalutamide resistance status (Fig. 1B). AR-V7 was significantly elevated in LNCaP clone 1 (highly resistant) compared with LNCaP control (sensitive) (p ≤ 0.001). AR-V7 was also higher in LNCaP clone 1 compared with LNCaP clone 9 (moderately resistant) (p ≤ 0.001). The expression of AR-FL (Fig. 1C) and AR-V7 (Fig. 1D) was confirmed using RNA in situ hybridisation (RISH) (BaseScope™). Qualitatively, AR-V7 expression varied across cell lines, with the highest expression in clone 1 and no expression detected in the control cell line (Fig. 1D). Enhanced levels of AR-V7 are associated with increased drug resistance.

circRNA screening identified differentially expressed profiles within an isogenic model of enzalutamide resistance. To determine differential expression of circRNAs within the drug sensitive (control) and resistant clones (clone 1 and clone 9), cell lines were screened for circRNA expression using a circRNA 2.0 microarray (Arraystar), which covers 13,617 circRNAs. In total, 930 circRNAs were classified as present across the panel of three cell lines. These target circRNAs were used for further differential analysis. The fold change (FC) for each circRNA between two groups (control vs. combined clone1/9) was calculated. A student’s paired t test was then used to identify significantly altered circRNAs. The false discovery rate (FDR) was applied to determine the threshold of p value. circRNAs with FC ≥ 1.5 and p < 0.05 were considered to be significantly differentially expressed. Grouped analysis (control vs. combined clone1/9) of detected circRNAs according to FC was performed. Overall, more circRNAs were significantly down-regulated in the enzalutamide resistant cell lines compared with the control. There were 278 circRNAs significantly up-regulated (p < 0.05, control vs. combined clone1/9) and 588 circRNAs that were significantly down-regulated (p < 0.05, control vs. combined clone1/9). Data is presented as a heat map in Fig. 2. A complete list of circRNAs is accessible through the GEO Series accession number GSE118959 and is provided in Supplementary Table 1.

The circRNA profile is further altered depending on the extent of enzalutamide resistance. Differential circRNA expression was also evident depending upon the extent of enzalutamide resistance (Fig. 3).
Clone 1 vs. control. In clone 1, we identified 230 up-regulated circRNAs ($p < 0.05$, vs. control), and 465 that were down-regulated ($p < 0.05$, vs. control). Thus, indicating the changing levels of circRNAs as enzalutamide resistance develops and levels of AR-V7 increases. Data is shown as a scatterplot and associated heatmap in Fig. 3A,C. A complete list of circRNAs is provided in Supplementary Table 2.

Clone 9 vs. control. In terms of clone 9, we discovered 60 up-regulated circRNAs ($p < 0.05$, vs. control), and 175 that were down-regulated ($p < 0.05$, vs. control). Data is shown as a scatterplot and associated heatmap in Fig. 3B,D. A complete list of circRNAs is provided in Supplementary Table 3. A Venn diagram is provided to show the overlap and different levels of expression between clone 1 and clone 9 with control (Fig. 3E). This Venn diagram display 585 circRNAs that were differentially expressed clone 1 vs. control but not clone 9 (shown in red) and 125 differentially expressed circRNAs between clone 9 vs. control but not clone 1 (shown in light green). There were 111 differentially expressed circRNAs common to both clone 1 and clone 9 vs. control (dark green).

Data is accessible through the GEO Series accession number GSE118959 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118959).

Associated circRNA parental genes are involved in pro-oncogenic activities. The top 5 circRNAs, ranked by FC, are shown in Table 1 for clone 1 vs. control; and in Table 2 for clone 9 vs. control. The parental genes of differentially expressed circRNAs were obtained from circBASE database (www.circbase.org)39. hsa_circ_0001275 was up-regulated in clone 1 vs. control ($p = 0.047$). The associated parental gene is PLCL2. Previously, PLCL2 (Inactive phospholipase C-like protein 2) was identified as part of a 23-gene signature, which predicted metastatic-lethal PCa outcomes in men diagnosed with clinically localised PCa30. hsa_circ_0022392 was down-regulated clone 1 vs. control ($p = 0.0002$) and is associated with the gene FADS2 (Fatty acid desaturase 2), which may have a role to play in cancer development31. In clone 9, hsa_circ_0045697 is up-regulated ($p = 0.029$, vs. control) and is associated with the oncogene ITGB4 (Integrin Subunit Beta 4). Studies have shown that ITGB4 promotes prostate tumourigenesis32. Further information is outlined in Tables 1 and 2.
miRNAs are associated with circRNAs. circRNAs contain multiple sites called miRNA response elements (MREs) which are miRNA binding sites found on circRNAs. circRNAs can bind up to five different miRNAs. For this study, the miRNAs were predicted using Targetscan and miRanda bioinformatic platforms. This bioinformatics approach determined which probable miRNA was associated with each circRNA. For each identified circRNA, the top five most likely miRNA binding sites were predicted. The circRNAs were then filtered according to miRNAs that were strongly associated with PCa in the literature (Table 3), thus producing a list of ten relevant up-regulated and down-regulated circRNAs for validation (Table 4) (41). Further information relating to corresponding parental gene, MREs, miRNAs, and associated miRNA function is outlined in Table 4.

Figure 2. Heatmap demonstrating changes in circRNA expression in clone 1, and clone 9 vs. control. Unsupervised clustering (euclidean distance measure and the ‘average’ agglomeration method) was used for analysis (n = 3). Red indicates higher levels of expression, while green indicates lower levels of expression.
Figure 3. Scatterplot and matching heatmap of circRNA expression between (A) control and clone 1 and (B) control and clone 9. The values of X and Y axes in the scatterplot are the normalized signal values of the samples (log2 scaled) or the averaged normalized signal values of groups of samples (log2 scaled). The green lines in the scatterplot indicate FC. Heatmap reflects changes in expression using unsupervised clustering analysis (euclidean distance measure and the 'average' agglomeration method) (n = 3). Red indicates higher levels of expression, while blue indicates lower levels. circRNAs chosen for validation are outlined in smaller heat maps showing the top five up and down regulated circRNAs in clone 1 vs. control (C) and clone 9 vs. control (D) (n = 3). Green indicated reduced expression, with red indicating increased expression. (E) Venn diagram displaying differentially expressed and overlapping circRNAs between clone 1 and clone 9 vs. control.
### Table 1. Top five up and down-regulated circRNAs in clone 1 vs. control based on FC.

| CircRNA       | Genomic Location | Expression | Fold Change | p-value | Parental Gene | Gene Function                                                                 |
|---------------|------------------|------------|-------------|---------|---------------|--------------------------------------------------------------------------------|
| hsa_circ_0001275 | chr3:17059499-17059748 | up         | 5.8         | 0.0473  |                | PLCL2 Complimentary to Gleason score for the prognostic classification of patients PCa |
| hsa_circ_0026462 | chr12:53068519-53069224 | up         | 5.7         | 0.0260  | KRT1          | Target receptor highly expressed on breast cancer cells                                  |
| hsa_circ_0033144 | chr14:99723807-99724176 | up         | 5.2         | 0.0128  | BCL11B        | Methylated in PCa                                                                        |
| hsa_circ_0000673 | chr16:11940357-11940700 | up         | 4.2         | 0.0383  | RSL1D1        | Overexpression is associated with an aggressive phenotype and poor prognosis in patients with PCa |
| hsa_circ_000129  | chr1:151145974-151149507 | down       | 3.9         | 0.0385  | VPS72         | May have a role in regulating long-term hematopoietic stem cell activity                  |

### Table 2. Top five up and down-regulated circRNAs in clone 9 vs. control based on FC.

| CircRNA       | Genomic Location | Expression | Fold Change | p-value | Parental Gene | Gene Function                                                                 |
|---------------|------------------|------------|-------------|---------|---------------|--------------------------------------------------------------------------------|
| hsa_circ_0004870 | chr7:3736438-73735899 | up         | 4.7         | 0.0297  |                | ITGB4 Involved in prostate tumor genesis and cancer invasiveness                    |
| hsa_circ_0000463 | chr12:132609079-132609271 | up         | 4.0         | 0.0088  | EF400NL       | Pseudogene                                                                      |
| hsa_circ_0026462 | chr12:53068519-53069224 | up         | 3.5         | 0.0254  | KRT1          | Target receptor highly expressed on breast cancer cells                              |
| hsa_circ_0000673 | chr16:11940357-11940700 | up         | 3.5         | 0.0054  | RSL1D1        | Overexpressed in PCa                                                                    |
| hsa_circ_0071174 | chr4:151656409-151729550 | down       | 2.4         | 0.0031  | LRBA          | LRBA has been implicated in regulating endosomal trafficking, particularly endocytosis of lipid-activated receptors |

### Validation of circRNAs.

Custom designed outward facing primers were designed for use with qPCR for selected circRNAs (Table 5). hsa_circ_0001721 was significantly up-regulated in clone 1 vs. control (p ≤ 0.05), which corresponded to the array data (Fig. 4A). Similarly, hsa_circ_0001721 was significantly up-regulated in the more resistant clone 1 vs. clone 9 (p ≤ 0.05) (Fig. 4A). hsa_circ_0001721 is an exonic circRNA, located on chromosome 7 and is associated with the gene CDK14 which corresponded to the array data (Fig. 4A). Similarly, hsa_circ_0001721 was significantly up-regulated in clone 9 (p ≤ 0.05) vs the more resistant clone 1.

### hsa_circ_0004870 may have a role in splicing via U2AF65.

Previous studies have demonstrated that circRNAs are down-regulated in cancer, therefore we selected hsa_circ_0004870 for further investigation. We confirmed that hsa_circ_0004870 was down-regulated in LNCaP (p ≤ 0.01) compared with the benign prosstatic hyperplasia line, BPH1 (Fig. 5A). Similarly, hsa_circ_0004870 was down-regulated in the AR positive 22Rv1 cell line (p ≤ 0.01) compared with the AR independent line, DU154 (Fig. 5B). The coordinates for hsa_circ_0004870 (chr20:34,302,106-34,313,077), correspond to the gene RBM39 on the UCSC Genome Browser, thus identifying this as the parental gene. RBM39 is a serine/arginine-rich RNA-binding protein thought to activate or inhibit the alternative splicing of specific mRNA by interacting with the spliceosomal components within splice sites. RBM39 was significantly down-regulated in the resistant clones 1 and 9 vs. control (p ≤ 0.05) (Fig. 4B). hsa_circ_0004870 is an exonic circRNA located on chromosome 20 and is associated with the gene RBM39.

### Conclusion

circRNAs have been identified in a number of different cancers (90), suggesting a potential role as a biomarker or therapeutic target. Although, their role in cancer has yet to be fully elucidated, recent research suggests they can act as miRNA sponges (170), bind RNA-binding proteins (RBPs), translate peptides (83) and may confer...
resistance to therapy (192). In this study, we report for the first time, to the best of our knowledge, circRNA expression profiles associated with enzalutamide resistant PCa. Our findings indicate that circRNAs may potentially represent valuable prognostic and diagnostic biomarkers in the real time monitoring of treatment response to enzalutamide. Given that other studies have shown circRNAs to be abundant, highly stable, and detectable in human saliva, tissue and blood samples22,39, their potential as liquid based biopsy markers is evident, in addition to their capacity to serve as a predictive marker in this disease.

Methods
Cell lines. The isogenic enzalutamide resistance LNCaP model was gifted from Novartis12. The panel consisted of an aged match control cell line (drug sensitive), and two sub-lines termed clone 1 and clone 9. Clone 1 was most resistance to the drug, with clone 9 displaying moderate resistance. Cells were cultured in RPMI-1640 media (Merck KGaA, Darmstadt, Germany) with 10% FBS (Merck KGaA) and 1% Penicillin Streptomycin (Merck KGaA). PC-3 were cultured in ATCC-formulated F-12K Medium containing 10% FBS and 1% Penicillin Streptomycin (Thermo Fisher Scientific, CA, US).

RNA preparation. Total RNA was prepared from cell lines from three independent experiments using TRizol (Life Technologies, CA, USA) according to manufacturer’s instructions. Subsequently, the RNA underwent DNase treatment with Ambion® TURBO DNase (Thermo Fisher Scientific, MA, USA) and a further RNA clean-up was performed using standard ethanol precipitation protocol.

Table 3. miRNAs associated with circRNAs, with a known involvement in PCa.

| CircRNA              | Genomic Location          | Expression | Fold Change | p-value | Parental Gene | MRE  | Gene Function                           |
|----------------------|---------------------------|------------|-------------|---------|---------------|------|----------------------------------------|
| hsa_circ_0004870     | chr20:34302106-34313077  | down       | 2.4         | 0.0015  | RBM153       | miR-145 | Cancer cell migration and invasion56 |
| hsa_circ_0002807     | chr13:114149816-114164739| down       | 1.7         | 0.0009  | TMCO3        | miR-141 | Suppresses stem cells17             |
| hsa_circ_002383      | chr11:61605249-61615756  | down       | 6.1         | 0.0244  | FADS2        | miR-124 | Inhibits invasion and proliferation31 |
| hsa_circ_0003505     | chr17:20910208-20911309  | down       | 1.6         | 0.0421  | USP22        | miR-124 | Inhibits invasion and proliferation31 |
| hsa_circ_0088059     | chr9:114905750-114905903 | down       | 2.5         | 0.0281  | SUSDI        | miR-124 | Inhibits invasion and proliferation31 |
| hsa_circ_0000673     | chr16:11940357-11940700  | up         | 3.5         | 0.0053  | RSL1D1       | miR-25  | Modulates invasiveness and dissemination25 |
| hsa_circ_0002754     | chr8:41905895-41907225   | up         | 2.3         | 0.0493  | KAT6A        | miR-145 | Cancer cell migration and invasion35,53 |
| hsa_circ_0001278     | chr3:31617887-31621588   | up         | 1.6         | 0.0004  | STT3B        | miR-205 | ERG target gene28                      |
| hsa_circ_0001721     | chr7:90355880-90356126   | up         | 1.9         | 0.0103  | CDK7        | miR-221 | Promotes cell proliferation and represses apoptosis30 |
| hsa_circ_0083092     | chr7:155471301-155473602 | up         | 2.4         | 0.0051  | RBM33        | miR-125b | Tumour suppressor37                  |

Table 4. List of circRNAs selected for validation with their corresponding parental gene, MREs, miRNAs, and associated miRNA function.
circRNA microarray. Cell line (from three independent biological replicates) analysis was performed using the Arraystar Human circRNA Array version 2.0 (Arraystar, Rockville, MD, USA). The sample preparation and microarray hybridization were performed according to manufacturer's instructions. Briefly, total RNA was digested with RNase R (Epicentre, Illumina, San Diego, CA, USA) to remove linear RNAs and enrich for circRNA. The enriched circRNAs were amplified and transcribed into fluorescent cRNA utilizing a random priming method Arraystar Super RNA Labelling Kit (Arraystar). The labelled cRNAs were hybridized onto the Arraystar Human circRNA Array V2 (8 × 15 K). The array slides were washed and scanned on the Agilent Scanner G2505C. Agilent Feature Extraction software (version 11.0.1.1) was used to analyse acquired array images.

Microarray data analysis. Quantile normalization and subsequent data processing were executed using R software package[^43]. CircRNAs with at least 4 out of 8 samples that were flagged as present or marginal (an attribute that denotes the quality of the entities) were considered to be target circRNAs according to GeneSpring software’s definitions and instructions. CircRNA and miRNA interactions were predicted with the Arraystar’s miRNA target prediction software based on TargetScan[^33] and miRanda[^34]. These target circRNAs were used for further differential analysis.

[Table 5. Primers used in this study.]

| circRNA   | Primer Sequence (5'→3')                          |
|-----------|--------------------------------------------------|
| 000487    | F: TGGGAACAACCTTGCTGTCTT                      |
|           | R: CTTTGTGAATTCTTGTGCTGTCT                      |
| 0001278   | F: CGGTCAGTAGCTGAGTCTT                        |
|           | R: ACCATGCTCTTTTATCAACAAAACCA                  |
| 0002807   | F: TTTCCACGTTGCTGTCTCTCTGT                     |
|           | R: ACAATGCAATCCAGGGCTCTCTCTCT                  |
| 0022383   | CCACAAGGATCCCGAGTTGAA                          |
|           | TTCACCAATCAGCAGGCTT                            |
| 0003505   | GGGGAAATCTCAAGCTGTATG                         |
|           | CAACGCGCTGCACATATGCT                          |
| 000673    | TGACTGTATAGGGTGAACAGTCT                       |
|           | AAAACTGCTGAGAAGGGCAGA                         |
| 0002754   | ACCAAATGGATGGAAGAAGA                          |
|           | TCCCCAADAAAATACTGACAC                        |
| 001278    | CGGTCAGTAGCTGAGTCTT                          |
|           | ACCATGCTCTTTTATCAACAAAACCA                    |
| 001721    | TCCTCCACTGGCAAAGAGTCT                       |
|           | CAGGAATTGTTGTCAGGGGTT                        |
| 0083092   | CCAGAGGAGGAGCCAGCTTAC                        |
|           | CCAGAGGAGGAGCCAGCTTAC                       |

[Figure 4. Validation of candidate circRNAs in an isogenic model of enzalutamide resistance. (A) hsa_circ_0001721 and (B) hsa_circ_0004870. Data graphed as mean ± SEM (n = 3). Ordinary one-way ANOVA (*p < 0.05).]

[^43]: R software package
[^33]: TargetScan
[^34]: miRanda
Quantitative real-time PCR. cDNA was synthesized from 1 μg RNA using a High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). The qPCR analyses were performed on a 7500 Real-Time PCR System using SYBR™ Green (Thermo Fisher Scientific). Primers are outlined in Table 5. GAPDH was used as reference gene. The relative expression and fold change of each gene was calculated using the delta delta Ct method.

RNA in situ hybridisation. The BaseScope™ (Advanced Cell Diagnostics, CA, USA) assays were performed manually according to the manufacturer's instructions. This method allows the detection of exon junctions and the analysis of splice variants. Briefly, the BaseScope™ assay procedure included the following steps: FFPE sections were deparaffinised and treated sequentially with specific pre-treatments to allow for target probe access. Target probes were added onto the slides and incubated in the HybEZ oven (Advanced Cell Diagnostics) for 2 h at 40 °C to allow probe hybridization to RNA targets. The slides were washed and incubated with a series of signal amplification solutions. The signal was amplified using a multi-step process, and detected using a red chromogenic substrate (10 min at room temperature). The slides were counterstained with haematoxylin and mounted with Cytoseal mounting medium (Richard-Allan Scientific, CA, USA).

Figure 5. hsa_circ_0004870 expression according to (A) malignancy status and (B) androgen dependency. Data graphed as mean ± SEM (n = 3). Ordinary one-way ANOVA (*p < 0.05, ****p ≤ 0.0001).

Figure 6. Expression of (A) RBM39 (B) and U2AF65 in the isogenic model of enzalutamide resistance. Data graphed as mean ± SEM (n = 3). Ordinary one-way ANOVA (**p < 0.01).
GEO files. The data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus28 and are accessible through GEO Series accession number GSE118959 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118959).

References
1. Nelson, W. G., De Marzo, A. M. & Isaacs, W. B. Prostate Cancer. New England Journal of Medicine 349, 366–381, https://doi.org/10.1056/NEJMoa121562 (2003).
2. Heidenreich, A. et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65, 467–479, https://doi.org/10.1016/j.eururo.2013.11.002 (2014).
3. Mellado, B., Codony, J., Ribal, M. J., Visa, L. & Gascon, P. Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 11, 5–10 (2009).
4. Scher, H. I. et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. New England Journal of Medicine 367, 1187–1197, https://doi.org/10.1056/NEJMoa1207506 (2012).
5. Beer, T. M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. The New England journal of medicine 371, 424–433, https://doi.org/10.1056/NEJMoa1405995 (2014).
6. Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. The New England journal of medicine 371, 1028–1038, https://doi.org/10.1056/NEJMoa1315815 (2014).
7. Visakorpi, T. et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature genetics 9, 401–406 (1995).
8. Liu, L. L. et al. Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene 33, 3140–3150 (2014).
9. Onstenk, W. et al. Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. Eur Urol 15, 00611–00619 (2015).
10. Antonarakis, E. S. et al. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol 4 (2015).
11. Nakazawa, M. et al. Serial Blood-Based Analysis of AR-V7 in Men with Advanced Prostate Cancer. Ann Oncol 27 (2015).
12. Korpal, M. et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov 3, 1030–1043, https://doi.org/10.1158/2159-8290.cd-13-0142 (2013).
13. Joseph, J. D. et al. A clinically relevant androgen receptor mutation confers resistance to second-generation androgenengphans enzalutamide and ARN-509. Cancer Discov 3, 1020–1029, https://doi.org/10.1158/2159-8290.CD-13-0226 (2013).
14. Yi, Y. et al. RAID v2.0: an updated resource of RNA-associated interactions across organisms. Nucleic Acids Res 45, D115–d118, https://doi.org/10.1093/nar/gkw1052 (2017).
15. Zhang, T. et al. RNALocate: a resource for RNA subcellular localizations. Nucleic Acids Res 45, D135–d138, https://doi.org/10.1093/nar/gkw278 (2017).
16. Bolton, E. M., Tzouva, A. V., Walsh, A. L., Lynch, T. & Ferry, A. S. Noncoding RNAs in prostate cancer: the long and the short of it. Clin Cancer Res 20, 35–43 (2014).
17. Bachmayr-Heyda, A. et al. Correlation of circular RNA abundance with proliferation - exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues. Scientific reports 5, 8057, https://doi.org/10.1038/srep08057 (2015).
18. Hansen, T. B., Kjems, J. & Damgaard, C. K. Circular RNA and miR-7 in cancer. Cancer research 73, 5609–5612, https://doi.org/10.1158/0008-5472.can-13-1568 (2013).
19. Greene, J. et al. Circular RNAs: Biogenesis, Function and Role in Human Diseases. Frontiers in molecular biosciences 4, 38, https://doi.org/10.3389/fmolb.2017.00038 (2017).
20. Salzman, J., Gawad, C., Wang, P. L., Lacayo, N. & Brown, P. O. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS One 7, 1 (2012).
21. Memczak, S. et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495, 333–338 (2013).
22. Salzman, J., Chen, R. E., Olsen, M. N., Wang, P. L. & Brown, P. O. Cell-type specific features of circular RNA expression. PLoS Genet 9, 5 (2013).
23. Kong, Z. et al. Androgen-responsive circular RNA circSMARCA5 is up-regulated and promotes cell proliferation in prostate cancer. Biochem Biophys Res Commun 493, 1217–1223, https://doi.org/10.1016/j.bbrc.2017.07.162 (2017).
24. He, J., Xie, Q., Xu, H., Li, J. & Li, Y. Circular RNAs and cancer. Cancer Letters 396, 138–144, https://doi.org/10.1016/j.canlet.2017.03.027 (2017).
25. Guarnerio, J. et al. Oncogenic Role of Fusion-circRNAs Derived from Cancer-Associated Chromosomal Translocations. Cell 165, 289–302 (2016).
26. Romero-Cordoba, S. L., Salido-Guadarrama, I., Rodriguez-Dorantes, M. & Hidalgo-Miranda, A. miRNA biogenesis: biological impact in the development of cancer. Cancer biology & therapy 15, 1444–1455, https://doi.org/10.4161/15384047.2014.955442 (2014).
27. Wang, S. et al. Expression of Androgen Receptor Variant 7 (AR-V7) in Circulated Tumor Cells and Correlation with Drug Resistance of Prostate Cancer Cells. Medical science monitor: international medical journal of experimental and clinical research 24, 7051–7056, https://doi.org/10.12659/MSM.990669 (2018).
28. Edgar, R., Domrachev, M. & Lash, A. E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Research 30, 207–210 (2002).
29. Glazar, P., Papavasileiou, P. & Rajewsky, N. circBase: a database for circular RNAs. rna 20, 1666–1670, https://doi.org/10.1261/rna.043687.113 (2014).
30. Rubicz, R. et al. Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer. Molecular oncology 11, 140–150, https://doi.org/10.1002/1878-0261.12014 (2017).
31. Park, W. J., Kothapalli, K. S. D., Lawrence, P. & Brenna, J. T. FADS2 Function Loss at the Cancer Hotspot 11q13 Locus Diverts Lipid Signaling Precursor Synthesis to Unusual Eicosanoid Fatty Acids. PLoS One 6, e28186, https://doi.org/10.1371/journal.pone.0028186 (2011).
32. Yoshioha, T. et al. 4 Integrin signaling induces expansion of prostate tumor progenitors. The Journal of Clinical Investigation 123, 682–699, https://doi.org/10.1172/JCI80720 (2013).
33. Agan, V. V., Bell, G. W., Nam, J.-W. & Bartel, D. P. Predicting effective microRNA target sites in mammalian mRNAs. eLife 4, e05005, https://doi.org/10.7554/eLife.05005 (2015).
34. John, B. et al. Human MicroRNA Targets. PLoS Biology 2, e63, https://doi.org/10.1371/journal.pbio.0020363 (2004).
35. Wang, L. et al. Effects of microRNA-221/222 on cell proliferation and apoptosis in prostate cancer cells. Gene 572, 252–258, https://doi.org/10.1016/j.gene.2015.07.017 (2015).
36. Li, S. M. et al. The putative tumour suppressor miR-1-3p modulates prostate cancer cell aggressiveness by repressing E2FS and PFKT1. Journal of experimental & clinical cancer research: CR 37, 219–219, https://doi.org/10.1186/s13046-018-0895-z (2018).
37. Mai, S. et al. Global regulation of alternative RNA splicing by the SR-rich protein RBM39. Biochimica et biophysica acta 1859, 1014–1024, https://doi.org/10.1016/j.bbagen.2016.06.007 (2016).
38. Zhang, Z. et al. Regulation of androgen receptor splice variant AR3 by PCGEM1. Oncotarget 7, 15481–15491, https://doi.org/10.18632/oncotarget.7139 (2016).
39. Bahn, J. H. et al. The landscape of microRNA, PwI-interacting RNA, and circular RNA in human saliva. Clin Chem 61, 221–230 (2015).
40. Dean, C. B. & Nielsen, J. D. Generalized linear mixed models: a review and some extensions. Lifetime data analysis 13, 497–512, https://doi.org/10.1007/s10985-007-9069-x (2007).
41. Soudy, R., Etayash, H., Bahadorani, K., Lavasanifar, A. & Kaur, K. Breast Cancer Targeting Peptide Binds Keratin 1: A New Molecular Marker for Targeted Drug Delivery to Breast Cancer. Molecular pharmaceutics 14, 593–604, https://doi.org/10.1012/acs.molpharmaceut.6800652 (2017).
42. Mahapatra, S. et al. Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res 18, 2882–2895, https://doi.org/10.1158/1078-0432.Ccr-11-2090 (2012).
43. Li, X. P. et al. Overexpression of ribosomal L1 domain containing 1 is associated with an aggressive phenotype and a poor prognosis in patients with prostate cancer. Oncology Letters 11, 2839–2844, https://doi.org/10.3892/ol.2016.4294 (2016).
44. Horikawa, I., et al. Forced expression of YL-1 protein suppresses the anchorage-independent growth of Kirsten sarcoma virus-transformed NIH3T3 cells. Experimental cell research 220, 11–17, https://doi.org/10.1016/0014-4827(95)90032-7 (1995).
45. Berquin, I. M., Edwards, I. J., Kridel, S. J. & Chen, Y. Q. Polyunsaturated fatty acid metabolism in prostate cancer. Cancer metastasis reviews 30, https://doi.org/10.1007/s10623-011-9399-7 (2011).
46. Martens-Uzunova, E. S., Olvedy, M. & Jenster, G. Beyond microRNA – Novel RNAs derived from small non-coding RNA and their implication in cancer. Cancer Letters 340, 201–211, https://doi.org/10.1016/j.canlet.2012.11.058 (2013).
47. Martínez Jaramillo, C. & Trujillo-Vargas, C. M. LR3A in the endomembrane system. Colombia medica (Cali, Colombia) 49, 236–243, https://doi.org/10.25310/cm.v49i12.3802 (2018).
48. Gissia, G. et al. Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proceedings of the National Academy of Sciences of the United States of America 109, 11252–11257, https://doi.org/10.1073/pnas.120853109 (2012).
49. Wang, R. et al. Preclinical study using small interfering RNA or Androgen receptor splicing variant 7 degradation enhancer ASC-J9to Suppress Enzalutamide-resistant Prostate Cancer Progression. European Urology 72, 835–844, https://doi.org/10.1016/j.eurouro.2017.04.005.
50. Chen, J. et al. Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer. Cancer Letters 388, 208–219, https://doi.org/10.1016/j.canlet.2016.12.006 (2017).
51. Liu, C. et al. MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nat Commun 8, 14270, https://doi.org/10.1038/ncommunications14270 (2017).
52. Shi, X. et al. Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene 32, 4143–4158, https://doi.org/10.1038/onc.2012.425 (2013).
53. Zoni, E. et al. miR-25 Modulates Invasiveness and Dissemination of Human Prostate Cancer Cells via Regulation of alpha6-Integrin Expression. Cancer research 75, 2326–2336, https://doi.org/10.1158/0008-5472.Can-14-2155 (2015).
54. Chen, Y. et al. Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status. Oncotarget 6, 31203–31215, https://doi.org/10.18632/oncotarget.4522 (2015).
55. Larne, O. et al. miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis. Carcinogenesis 36, 858–866, https://doi.org/10.1093/carcin/bgv063 (2015).
56. Wang, N. et al. miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth. Asian Journal of Andrology 15, 735–741, https://doi.org/10.18632/oncotarget.4522 (2013).
57. Rudd, W. T. et al. Dual Action of miR-125b As a Tumor Suppressor and OncomiR-22 Promotes Prostate Cancer Tumorigenesis. PLoS One 10, e0142373, https://doi.org/10.1371/journal.pone.0142373 (2015).

Acknowledgements
This work was supported by a Prostate Cancer Foundation Young Investigator Award (SPF) and the Irish Cancer Society (SPF).

Author Contributions
J.G., A.M.B., S.G.G., R.M.D. and S.P.F. designed the study and developed the methodology. J.G. performed the experiments, collected and analysed data with assistance from A.M.B., L.B., G.B., M.L. and O.O.B. The manuscript was written by J.G. and A.M.B. with reviews and contributions from S.G.G., R.M.D. and S.P.F.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s14598-019-47189-2.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019